Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05169333 · ClinicalTrials.gov registry record

The Oxford Risk Factors And Non-Invasive Imaging Study

A clinical trial of Cardiovascular Diseases and Cardiovascular Risk Factors, sponsored by University of Oxford.

Recruiting
Registry status
250,000
Enrollment target
20
Study locations

NCT05169333: Recruiting study of Cardiovascular Diseases and Cardiovascular Risk Factors, sponsored by University of Oxford.

NCT05169333 is a study of Cardiovascular Diseases and Cardiovascular Risk Factors that is actively recruiting participants, run by University of Oxford. The registered enrollment target is 250,000 participants, above the 26,141-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (856% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05169333, a study of Cardiovascular Diseases and Cardiovascular Risk Factors, is actively recruiting participants, sponsored by University of Oxford.

RECRUITING
Registry status
250,000 participants
Enrollment target
20
Study locations

Study Summary

ORFAN is a prospective, multi-centre, multi-ethnic cohort observational study collecting CT scans, biological material and outcomes data, to develop and validate novel biomarkers of cardiometabolic and other disease risk.

Primary Outcome

Using novel image analysis methods, clinical risk factors, and blood biomarkers to predict future cardiac and all-cause mortality over a period of 15 years post CT scan.

Study Locations (20)

Other

  • Flinders University - Adelaide
  • The University of Sydney - Sydney
  • University Hospitals Leuven - Leuven
  • Fudan University - Shanghai
  • TEDA International Cardiovascular Hospital - Tianjin
  • Almaviva Sante - Clinique Axium - Aix-en-Provence
  • Friedrich-Alexander-Universitat Erlangen-Nurmberg - Erlangen
  • University Hospital Ulm - Ulm
  • Lefkos Stavros Clinic - Athens
  • MTA-SE Cardiovascular Imaging Research Group - Budapest
  • Centro Cardiologico Monzino IRCCS, University of Milan - Milan
  • Oita University - Ōita
  • Amsterdam Universitair Medische Centra - Amsterdam
  • Zuyderland Medical Centre - Sittard
  • University of Medicine and Pharmacy of Targu Mures - Târgu Mureş
  • Seoul National University - Seoul
  • Cleveland Clinic Abu Dhabi - Abu Dhabi

Maryland

  • NIH National Heart, Lunch, and Blood Institute - Bethesda

Minnesota

  • Mayo Clinic - Rochester

Ohio

  • Cleveland Clinic Heart and Vascular Institute - Cleveland

Trial Details

FieldValue
Enrollment Target 250,000 participants
Start Date 2016-02-23
Est. Completion 2030-02
University of Oxford

5 total trials

What NCT05169333 shows while recruiting

NCT05169333 is an observational study that tracks outcomes without assigning an intervention. Its 250,000 participants enrollment target places it among the larger protocols in the corpus, above the 26,141-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (856% higher).

The record links to 2 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 0 interventions.

NCT05169333 names 20 study sites across 4 states, led by Other, Maryland, Minnesota.

Frequently Asked Questions

What is clinical trial NCT05169333 about?

NCT05169333 is a clinical study titled "The Oxford Risk Factors And Non-Invasive Imaging Study". ORFAN is a prospective, multi-centre, multi-ethnic cohort observational study collecting CT scans, biological material and outcomes data, to develop and validate novel biomarkers of cardiometabolic and other disease risk.

What is the current status of trial NCT05169333?

This trial is currently recruiting. The enrollment target is 250,000 participants. The study started on 2016-02-23. Estimated completion is 2030-02.

What conditions does trial NCT05169333 study?

This clinical trial studies the following conditions: Cardiovascular Diseases, Cardiovascular Risk Factors.

Who is sponsoring clinical trial NCT05169333?

This trial is sponsored by University of Oxford, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05169333 being conducted?

This trial has 20 study locations across Maryland, Minnesota, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cardiovascular Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05169333's enrollment target sits among peer trials

250,000 5th of 300 higher than 296 of 300 other Cardiovascular Diseases trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cardiovascular Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04735835 · 250,000 participants · NA

    Personalized Responses to Dietary Composition Trial 3

  • NCT02280733 · 300,000 participants

    A Real-World Registry of Chronic Wounds and Ulcers

  • NCT06694181 · 300,000 participants

    Safe and Explainable AI

  • NCT07314697 · 300,000 participants · NA

    Arrival Time Implementation

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05169333, the US trial registry maintained by the National Library of Medicine. NCT05169333 (large enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.